The fourth component, GHK-Cu, will be voted on in a subsequent February 2027 meeting HHS has announced that GHK-Cu is expected to return to Category 1 (after being moved to Category 2 in September 2023), which would restore compounding access for injectable formulations. The recommendations of the PCAC are non-binding but noteworthy
SGLT2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: a systematic review
Unless someone is engaging in prolonged physical activity of over 60 minutes per day at vigorous intensity or in high heat, has a medical condition requiring electrolyte replacement, or has been advised by a healthcare professional, daily electrolyte supplementation is unnecessary (AHA, 2024)
Since that time Ive lost seven lbs
Cost Plus Drug is already in business as an online pharmacy selling more than 100 medications, including for asthma, heart failure, and Parkinsons disease to mental health, allergies, and cancer